

Appendix 2: Excluded studies

1. Baur DM, Klotsche J, Hamnvik OPR, Sievers C, Pieper L, Wittchen HU, et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. *Metabolism: Clinical and Experimental* 2011;60(10):1363-71.
2. Bo S, Ciccone G, Rosato R, Villosi P, Appendino G, Ghigo E, et al. Cancer mortality reduction and metformin. A retrospective cohort study in type 2 diabetic patients. *Diabetes, Obesity and Metabolism* 2012;14(1):23-9.
3. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. *Cancer Epidemiology Biomarkers and Prevention* 2012;21(2):280-6.
4. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. *Pharmacoepidemiology And Drug Safety* 2011;20(Suppl 1):S270
5. Bodmer M, Becker C, Meier C, Jick SS, & Meier CR. Use of metformin and the risk of ovarian cancer: A case-control analysis. *Gynecologic Oncology* 2011;123(2):200-4.
6. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. *Diabetes Care* 2010;33(6):1304-8.
7. Bristol-Myers Squibb. A study assessing saxagliptin treatment in type 2 diabetic subjects who are not controlled with TZD therapy alone. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2012 Jun 06]. Available: <http://clinicaltrials.gov/show/NCT00295633> NLM Identifier: NCT00295633.
8. Caisse National d'Assurance Maladie. Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France : une étude de cohorte sur les données du SNIIRAM et du PMSI. Saint Denis 2011 [cited 2012 Jun 06]. Available: www.afssaps.fr/var/afssaps_site/storage/original/application/b42a6bf9a1b63c3dbec7388d3914687b.pdf.
9. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. *The New England Journal of Medicine* 2011;364(12):1104-15.
10. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn A-R. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes. *Drug Safety* 2009;32(3):187-202.
11. Eddi R, Karki A, Shah A, DeBari VA, DePasquale JR. Association of type 2 diabetes and colon adenomas. *Journal of Gastrointestinal Cancer* 2012;43(1):87-92.

12. El-Serag HB, Hachem C, Johnson ML, Morgan RO. Insulin treatment and risk of hepatocellular carcinoma in patients with diabetes. *Gastroenterology* 2009;136(5 Supplement 1):A126.
13. Ferrara A, Lewis JD, Quesenberry CP, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. *Diabetes care* 2011;34(4):923-9.
14. Fidan E, Onder Ersoz H, Yilmaz M, Yilmaz H, Kocak M, Karahan C, et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. *Acta Diabetologica* 2011;48(4):297-302.
15. GlaxoSmithKline. Rosiglitazone-metformin combination versus metformin-sulfonylurea combination on beta-cell function in type 2 diabetes. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2012 Jun 06]. Available: <http://clinicaltrials.gov/show/NCT00367055> NLM Identifier: NCT00367055.
16. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. *Journal of Clinical Oncology* 2007;25(12):1476-81.
17. Gray TC, Siegel E, Govindarajan R. Impact of antidiabetic agents on the survival of subjects with colorectal cancer (CRC). *Journal of Clinical Oncology* 2010;28(15 Suppl):2586.
18. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. *Cancer* 2010;116(8):1938-46.
19. He XX, Tu SM, Lee MH, Yeung SCJ. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. *Annals of Oncology* 2011;22(12):2640-5.
20. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. *Diabetologia* 2010;53(9):1838-45.
21. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. *Diabetologia* 2009;52(12):2499-506.
22. Kendall DM, Rubin CJ, Mohideen P, Ledezine J-M, Belder R, Gross J, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. *Diabetes Care* 2006;29(5):1016-23.
23. Kong APS, Yamasaki A, Ozaki R, Asami T, Ohwada S, Ko GTC, et al. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel

- PPAR gamma agonist on glucose-lipid control in type 2 diabetes. *Diabetes, Obesity and Metabolism* 2011;13(9):806-13.
24. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. *Pharmacoepidemiology and Drug Safety* 2007;16(5):485-92.
 25. Lai S-W, Chen P-C, Liao K-F, Muo C-H, Lin C-C, Sung F-C. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. *American Journal of Gastroenterology* 2012;107(1):46-52.
 26. Lai S-W, Liao K-F, Chen P-C, Tsai P-Y, Hsieh DPH, Chen C-C. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. *Clinical Lung Cancer* 2011;13(2):143-8.
 27. Lewis J, Ferrara A, Peng T, Hedderson M, Bilker W, Quesenberry C, et al. Relative risk of bladder cancer with pioglitazone for diabetes mellitus: mid-way report of a 10 year follow-up study. *Pharmacoepidemiology and Drug Safety* 2010;19(Suppl 1):S13.
 28. Lewis JD, Capra AM, Achacoso NS, Ferrara A, Levin TR, Quesenberry CP, et al. Medical therapy for diabetes is associated with increased use of lower endoscopy. *Pharmacoepidemiology and Drug Safety* 2007;16(11):1195-202.
 29. Lewis JD, Capra AM, Achacoso NS, Ferrara A, Levin TR, Quesenberry CP, et al. Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. *Gastroenterology* 2008;135(6):1914-23, 23 e1.
 30. Li D, Yeung S-CJ, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. *Gastroenterology* 2009;137(2):482-8.
 31. Liao K-F, Lai S-W, Li C-I, Chen W-C. Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. *Journal of Gastroenterology and Hepatology* 2012;27(4):709-13.
 32. Long M, Vinikoor L, Martin C, Galanko J, Keku T, Sandler R. Thiazolidinedione use and rectal cancer in diabetics: a population based case-control study. *American Journal of Gastroenterology* 2008;103(Suppl. S):S387.
 33. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. *Diabetes Care* 2010;33(9):1997-2003.
 34. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. *Acta Diabetologica* 2009;46(4):279-84.
 35. Murtola TJ, Tammela TLJ, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. *American Journal of Epidemiology* 2008;168(8):925-31.

36. National Cancer Institute. Pioglitazone to treat adults undergoing surgery for non-small cell lung cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2012 Jun 06]. Available: <http://clinicaltrials.gov/show/NCT00923949> NLM Identifier: NCT00923949.
37. Philips J-C, Petite C, Willi J-P, Buchegger F, Meier CA. Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. *Nuclear Medicine Communications* 2004;25(12):1183-6.
38. Powell LA, Crowe P, Kankara C, McPeake J, McCance DR, Young IS, et al. Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation. *Clinical Science* 2012;123(3):135-46.
39. Punthakee Z, Holman R, Probstfield JL, Riddle MC, Rydén LE, Zinman B, et al. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. *Diabetologia* 2012;55(1):36-45.
40. Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. *BMC Medicine* 2007;5:17.
41. Reyes-Morales H, Mino-León D, Doubova SV, Flores-Hernández S. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico. *International Journal of Clinical Pharmacology and Therapeutics* 2012;50(1):1-9.
42. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. *Diabetes Care* 2006;29(3):554-9.
43. Rutter MK, Nesto RW. The BARI 2D study: a randomised trial of therapies for type 2 diabetes and coronary artery disease. *Diabetes and Vascular Disease Research* 2010;7(1):69-72.
44. Segelov E, Darnell D, Morrow A, Greenfield J, Lepre F, Hoffman DM. Is bladder cancer more common in diabetics using pioglitazone? *Asia Pacific Journal of Clinical Oncology* 2011;7(Suppl 4):170.
45. Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. *Drug Safety* 2009;32(9):787-800.
46. Tseng C-H. Diabetes and risk of prostate cancer: a study using the National Health Insurance. *Diabetes Care* 2011;34(3):616-21.
47. Tungsiripat M, El-Bejjani D, Rizk N, Dogra V, O'Riordan MA, Ross AC, et al. Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV patients with lipotrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. *AIDS Research and Human Retroviruses* 2011;27(3):295-302.

48. van Staa TP, Patel D, Gallagher AM, De Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. *Diabetologia* 2011;55(3):654-65.
49. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. *Cancer Causes and Control* 2009;20(9):1617-22.
50. Wu LC, Chang CH, Chunag LM, Lai MS. Anti-diabetic therapies and cancer risk among type 2 diabetes patients in Taiwan-a nationwide nested case-control study. *Pharmacoepidemiology and Drug Safety* 2011;20(Suppl 1):S290.
51. Yang X, Ma RCW, Yu LWY, Ko GTC, Kong APS, Ng VWS, et al. Use of sulphonylurea and cancer in type 2 diabetes: The Hong Kong Diabetes Registry. *Diabetes Research and Clinical Practice* 2010;90(3):343-51.
52. Zhang H-T, Hammad TA, Christiani D. The risk of cancer associated with anti-diabetic agents. *Pharmacoepidemiology and Drug Safety* 2009;18(S1):S39.
53. Zhang Y, Vitry A, Caughey G, Roughead EE, Ryan P, Gilbert A, et al. The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes. *Diabetes Research and Clinical Practice* 2011;91(1):115-20.